{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:55:47Z","timestamp":1767135347391,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":86,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd010982","type":"reference-entry","created":{"date-parts":[[2014,3,24]],"date-time":"2014-03-24T22:31:30Z","timestamp":1395700290000},"source":"Crossref","is-referenced-by-count":5,"title":["Alternative agents versus prophylactic platelet transfusion for preventing bleeding in patients with haematological disorders after chemotherapy or stem cell transplantation"],"prefix":"10.1002","author":[{"given":"Lise J","family":"Estcourt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Gregg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Stanworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Doree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialena","family":"Trivella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Tinmouth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,19]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD010982-BIB1|cit1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0049-3848(83)90326-2","article-title":"DDAVP: Does the drug have a direct effect on the vessel wall?","volume":"31","author":"Barnhart","year":"1983","journal-title":"Thrombosis Research"},{"key":"10.1002\/14651858.CD010982-BIB2|cit2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2141.2003.04468.x","article-title":"Guidelines for the use of platelet transfusions","volume":"122","year":"2003","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD010982-BIB3|cit3","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2141.2004.04815.x","article-title":"Transfusion guidelines for neonates and older children","volume":"124","year":"2004","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD010982-BIB4|cit4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1365-2141.2009.07840.x","article-title":"Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill","volume":"147","author":"Benson","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010982-BIB5|cit5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/asheducation-2008.1.198","article-title":"New strategies for the optimal use of platelet transfusions","volume":"1","author":"Blajchman","year":"2008","journal-title":"Hematology (American Society of Hematology Education Program)"},{"key":"10.1002\/14651858.CD010982-BIB6|cit6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12026-009-8106-9","article-title":"The platelet as an immune cell - CD40 ligand and transfusion immune modulation","volume":"45","author":"Blumberg","year":"2009","journal-title":"Immunology Research"},{"key":"10.1002\/14651858.CD010982-BIB7|cit7","first-page":"372","article-title":"Platelet concentrates. Cross-sectional guidelines for therapy with blood components and plasma derivatives","volume":"36","year":"2009","journal-title":"Transfusion Medicine and Hemotherapy"},{"key":"10.1002\/14651858.CD010982-BIB8|cit8","volume-title":"The 2011 Annual SHOT Report","year":"2012"},{"issue":"4","key":"10.1002\/14651858.CD010982-BIB9|cit9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: Results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD010982-BIB10|cit10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009072.pub2","article-title":"Pathogen-reduced platelets for the prevention of bleeding","author":"Butler","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010982-BIB11|cit11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1537-2995.2007.01090.x","article-title":"Evaluation of platelet transfusion triggers in a tertiary-care hospital","volume":"47","author":"Cameron","year":"2007","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD010982-BIB12|cit12","unstructured":"Cancer Research UK Percentage change in european age-standardised three year average incidence rates, males, UK, 1991-2001 and 2008-2010 Cancer Research UK statistics at http:\/\/www.cancerresearchuk.org\/cancer-info\/cancerstats\/ [Accessed 14\/02\/2013]"},{"key":"10.1002\/14651858.CD010982-BIB13|cit13","unstructured":"CDC (Center for Disease Control) United States Cancer Statistics National Program of Cancer Registries (NPCR) 2012 [Accessed 14\/02\/2013]"},{"issue":"7","key":"10.1002\/14651858.CD010982-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjc.6601696","article-title":"Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001","volume":"90","author":"Coleman","year":"2004","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD010982-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1537-2995.2004.03231.x","article-title":"Methods for the analysis of bleeding outcomes in randomized trials of platelet transfusion triggers","volume":"44","author":"Cook","year":"2004","journal-title":"Transfusion"},{"issue":"7","key":"10.1002\/14651858.CD010982-BIB16|cit16","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin","volume":"111","author":"Serna","year":"2008","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982-BIB17|cit17","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"28","key":"10.1002\/14651858.CD010982-BIB18|cit18","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1002\/adma.201200607","article-title":"Platelet mimetic particles for targeting thrombi in flowing blood","volume":"24","author":"Doshi","year":"2012","journal-title":"Advanced Materials"},{"key":"10.1002\/14651858.CD010982-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jama.1910.04330140029009","article-title":"The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and coagulation time and report of 3 cases of hemorrhagic disease relieved by transfusion","volume":"55","author":"Duke","year":"1910","journal-title":"Journal of the American Medical Association"},{"issue":"4","key":"10.1002\/14651858.CD010982-BIB20|cit20","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2141.2010.08483.x","article-title":"Platelet transfusions for patients with haematological malignancies: who needs them?","volume":"154","author":"Estcourt","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD010982-BIB21|cit21","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1423-0410.2012.01627.x","article-title":"Platelet transfusions in haematology patients: are we using them appropriately?","volume":"103","author":"Estcourt","year":"2012","journal-title":"Vox Sanguinis"},{"issue":"7","key":"10.1002\/14651858.CD010982-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/trf.12058","article-title":"Differences in the methods of assessing and analysing bleeding outcomes in platelet transfusion trials","volume":"53","author":"Estcourt","year":"2013","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD010982-BIB23|cit23","article-title":"Does bleeding affect patient reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review","volume":"[Early on-line","author":"Estcourt","year":"2013","journal-title":"Transfusion"},{"issue":"3","key":"10.1002\/14651858.CD010982-BIB24|cit24","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"16","key":"10.1002\/14651858.CD010982-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2010.491","article-title":"Hematopoietic stem cell transplantation: a global perspective","volume":"303","author":"Gratwohl","year":"2010","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD010982-BIB26|cit26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1537-2995.2007.01089.x","article-title":"Platelet utilisation and the transfusion trigger: a prospective analysis","volume":"72","author":"Greeno","year":"2007","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD010982-BIB27|cit27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1046\/j.1537-2995.2003.00418.x","article-title":"Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies","volume":"43","author":"Heddle","year":"2003","journal-title":"Transfusion"},{"issue":"7","key":"10.1002\/14651858.CD010982-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/j.1537-2995.2008.01731.x","article-title":"Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review","volume":"48","author":"Heddle","year":"2008","journal-title":"Transfusion"},{"issue":"7","key":"10.1002\/14651858.CD010982-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood-2008-09-178236","article-title":"A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia","volume":"113","author":"Heddle","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982-BIB30|cit30","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/9781444311761.ch6","article-title":"Investigation of acute transfusion reactions","volume-title":"Practical Transfusion Medicine","author":"Heddle","year":"2009"},{"key":"10.1002\/14651858.CD010982-BIB31|cit31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1537-2995.1974.tb04558.x","article-title":"The prophylactic treatment of thrombocytopenic leukemic patients with platelets: a double blind study","volume":"14","author":"Higby","year":"1974","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD010982-BIB32|cit32","unstructured":"Higgins JPT Deeks JJ (editors) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010982-BIB33|cit33","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in Statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010982-BIB34|cit34","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010982-BIB35|cit35","volume-title":"The 2010 Annual SHOT Report","author":"Knowles","year":"2011"},{"key":"10.1002\/14651858.CD010982-BIB36|cit36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1537-2995.2004.03153.x","article-title":"Measurement of bleeding severity: a critical review","volume":"44","author":"Koreth","year":"2004","journal-title":"Transfusion"},{"issue":"3","key":"10.1002\/14651858.CD010982-BIB37|cit37","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/j.seminhematol.2010.02.005","article-title":"Biology and chemistry of thrombopoietic agents","volume":"47","author":"Kuter","year":"2010","journal-title":"Seminars in Hematology"},{"key":"10.1002\/14651858.CD010982-BIB38|cit38","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"12","key":"10.1002\/14651858.CD010982-BIB39|cit39","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1111\/j.1538-7836.2009.03633.x","article-title":"Pharmacokinetics and safety of fibrinogen concentrate","volume":"7","author":"Manco-Johnson","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"7","key":"10.1002\/14651858.CD010982-BIB40|cit40","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD010982-BIB41|cit41","first-page":"362","article-title":"Clinical study on platelet engraftment by thrombopoietin in patients with hematological malignancies after allogeneic hematopoietic stem cell transplantation","volume":"33","author":"Miao","year":"2012","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1002\/14651858.CD010982-BIB42|cit42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ajh.2830120406","article-title":"Indications for platelet transfusion in children with acute leukemia","volume":"12","author":"Murphy","year":"1982","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD010982-BIB43|cit43","volume-title":"The National Blood Authority\u2019s Patient Blood Management Guideline: Module 3 - Medical","year":"2012"},{"key":"10.1002\/14651858.CD010982-BIB44|cit44","unstructured":"NICE Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura TA205 National Institute for Clinical Excellence 2010"},{"key":"10.1002\/14651858.CD010982-BIB45|cit45","unstructured":"NICE Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura TA221 National Institute for Clinical Excellence 2011"},{"issue":"1","key":"10.1002\/14651858.CD010982-BIB46|cit46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood.V100.1.136","article-title":"Reconstitution of adhesive properties of human platelets in liposomes carrying both recombinant glycoproteins Ia\/IIa and Iba under flow conditions: specific synergy of receptor-ligand interactions","volume":"100","author":"Nishiya","year":"2002","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982-BIB47|cit47","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1021\/bc900325w","article-title":"Novel platelet substitutes: disk-shaped biodegradable nanosheets and their enhanced effects on platelet aggregation","volume":"20","author":"Okamura","year":"2009","journal-title":"Bioconjugate Chemistry"},{"issue":"3","key":"10.1002\/14651858.CD010982-BIB48|cit48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1538-7836.2008.03269.x","article-title":"Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute","volume":"7","author":"Okamura","year":"2009","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD010982-BIB49|cit49","unstructured":"ONS Cancer incidence and mortality tables and charts Office of National Statistics 2012 [Accessed 14\/02\/2013]"},{"issue":"24","key":"10.1002\/14651858.CD010982-BIB50|cit50","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"7","key":"10.1002\/14651858.CD010982-BIB51|cit51","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2012.66","article-title":"The EBMT activity survey: 1990-2010","volume":"47","author":"Passweg","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1002\/14651858.CD010982-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.2009.008649","article-title":"Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission","volume":"94","author":"Patel","year":"2009","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD010982-BIB53|cit53","first-page":"ahead of print","article-title":"Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review","volume":"Epub","author":"Pavenski","year":"2013","journal-title":"Transfusion"},{"issue":"1","key":"10.1002\/14651858.CD010982-BIB54|cit54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-3148.2010.01037.x","article-title":"Screening of platelet for bacterial contamination at the Welsh Blood Service","volume":"21","author":"Pearce","year":"2011","journal-title":"Transfusion Medicine"},{"key":"10.1002\/14651858.CD010982-BIB55|cit55","first-page":"17","article-title":"An audit of use and wastage in the north west of England and North Wales: where have all the platelets gone?","volume":"34","author":"Pendry","year":"2011","journal-title":"Blood and Transplant Matters"},{"key":"10.1002\/14651858.CD010982-BIB56|cit56","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1046\/j.1537-2995.1985.25686071434.x","article-title":"Diagnostic and pathogenetic considerations in transfusion-related acute lung injury","volume":"25","author":"Popovsky","year":"1985","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD010982-BIB57|cit57","first-page":"351","article-title":"Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England","volume":"4","author":"Rachet","year":"10","journal-title":"The Lancet Oncology"},{"key":"10.1002\/14651858.CD010982-BIB58|cit58","unstructured":"The Nordic Cochrane Centre Review Manager (RevMan) 2012"},{"issue":"1","key":"10.1002\/14651858.CD010982-BIB59|cit59","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/09537100903388359","article-title":"Effect of beta-blockers, Ca2+antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia","volume":"21","author":"Rysler","year":"2010","journal-title":"Platelets"},{"key":"10.1002\/14651858.CD010982-BIB60|cit60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood.V64.1.229.229","article-title":"DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium","volume":"64","author":"Sakariassen","year":"1984","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1200\/JCO.2001.19.5.1519","article-title":"Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology","volume":"19","author":"Schiffer","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010982-BIB62|cit62","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010982-BIB63|cit63","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1111\/j.1537-2995.2009.02273.x","article-title":"ABO-identical versus non-identical platelet transfusion: a systematic review","volume":"49","author":"Shehata","year":"2009","journal-title":"Transfusion"},{"issue":"2","key":"10.1002\/14651858.CD010982-BIB64|cit64","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2002-03-0958","article-title":"Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors","volume":"101","author":"Silliman","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1002\/14651858.CD010982-BIB65|cit65","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005011.pub4","article-title":"Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia","author":"Simpson","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010982-BIB66|cit66","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev.me.31.020180.002453","article-title":"Controversies in platelet transfusion therapy","volume":"31","author":"Slichter","year":"1980","journal-title":"Annual Reviews of Medicine"},{"key":"10.1002\/14651858.CD010982-BIB67|cit67","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1182\/blood-2003-08-2724","article-title":"Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients","volume":"105","author":"Slichter","year":"2005","journal-title":"Blood"},{"key":"10.1002\/14651858.CD010982-BIB68|cit68","doi-asserted-by":"crossref","unstructured":"Slichter SJ Evidence-based platelet transfusion guidelines Hematology (American Society of Hematology Education Program) 2007 172 8","DOI":"10.1182\/asheducation-2007.1.172"},{"key":"10.1002\/14651858.CD010982-BIB69|cit69","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of haemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010982-BIB70|cit70","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(78)90505-6","article-title":"Platelet prophylaxis in acute non-lymphoblastic leukemia","volume":"1 (8058)","author":"Solomon","year":"1978","journal-title":"The Lancet"},{"issue":"5","key":"10.1002\/14651858.CD010982-BIB71|cit71","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/bja\/aeq058","article-title":"Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery","volume":"104","author":"Solomon","year":"2010","journal-title":"British Journal of Anaesthesia"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010982-BIB72|cit72","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0049-3848(12)70004-X","article-title":"The role of fibrinogen: a new paradigm in the treatment of coagulopathic bleeding","volume":"128","author":"S\u00f8rensen","year":"2011","journal-title":"Thrombosis Research"},{"issue":"3","key":"10.1002\/14651858.CD010982-BIB73|cit73","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.tmrv.2009.11.002","article-title":"Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions? Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet transfusions","volume":"24","author":"Stanworth","year":"2010","journal-title":"Transfusion Medicine Reviews"},{"issue":"19","key":"10.1002\/14651858.CD010982-BIB74|cit74","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","article-title":"A no-prophylaxis platelet transfusion strategy for hematologic cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010982-BIB75|cit75","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010982-BIB76|cit76","volume-title":"The 2009 Annual SHOT Report","author":"Taylor","year":"2010"},{"issue":"16","key":"10.1002\/14651858.CD010982-BIB77|cit77","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD010982-BIB78|cit78","article-title":"Chapter 18: Platelet transfusion, alloimmunization and management of platelet refractoriness","volume-title":"Canadian Blood Services","author":"Tinmouth","year":"2007"},{"key":"10.1002\/14651858.CD010982-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1056\/NEJM199712253372601","article-title":"Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions","volume":"337","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010982-BIB80|cit80","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.transci.2009.07.005","article-title":"Platelet utilization in the developing world: strategies to optimize platelet transfusion practices","volume":"41","author":"Verma","year":"2009","journal-title":"Transfusion and Apheresis Science"},{"issue":"9850","key":"10.1002\/14651858.CD010982-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(12)60689-8","article-title":"Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study","volume":"380","author":"Wandt","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD010982-BIB82|cit82","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009733.pub2","article-title":"Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders","author":"Wardrop","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010982-BIB83|cit83","volume-title":"WHO Handbook for Reporting Results of Cancer Treatment","author":"WHO","year":"1979"},{"issue":"7","key":"10.1002\/14651858.CD010982-BIB84|cit84","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008235.pub2","article-title":"TPO receptor agonist for chronic idiopathic thrombocytopenic purpura","author":"Zeng","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010982-BIB85|cit85","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004269.pub3","article-title":"Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation","author":"Estcourt","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD010982-BIB86|cit86","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004269.pub2","article-title":"Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation","author":"Stanworth","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010982.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:50:55Z","timestamp":1628535055000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010982"}},"subtitle":[],"editor":[{"given":"Lise J","family":"Estcourt","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,19]]},"references-count":86,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010982","relation":{},"subject":[],"published":{"date-parts":[[2014,3,19]]}}}